A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment

Trial Profile

A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 27 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 19 Dec 2017.
    • 21 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top